Drugs / Refralon
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05445297 | Jan 2022 → Jun 2023 | paroxysmal atrial fibrillation | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05456204 | Feb 2022 → Jun 2024 | atrial fibrillation, atrial flutter | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Refralon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05445297 ↗ |
| Route | Intravenous | “intravenous refralon” NCT05445297 ↗ |